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Abstract
Background: The New South Wales State Government recently proposed a trial of the medical
use of cannabis. Australians who currently use cannabis medicinally do so illegally and without
assurances of quality control. Given the dearth of local information on this issue, this study
explored the experiences of medical cannabis users.
Methods: Australian adults who had used cannabis for medical purposes were recruited using
media stories. A total of 147 respondents were screened by phone and anonymous questionnaires
were mailed, to be returned by postage paid envelope.
Results: Data were available for 128 participants. Long term and regular medical cannabis use was
frequently reported for multiple medical conditions including chronic pain (57%), depression (56%),
arthritis (35%), persistent nausea (27%) and weight loss (26%). Cannabis was perceived to provide
"great relief" overall (86%), and substantial relief of specific symptoms such as pain, nausea and
insomnia. It was also typically perceived as superior to other medications in terms of undesirable
effects, and the extent of relief provided. However, nearly one half (41%) experienced conditions
or symptoms that were not helped by its use. The most prevalent concerns related to its illegality.
Participants reported strong support for their use from clinicians and family. There was almost
universal interest (89%) in participating in a clinical trial of medical cannabis, and strong support
(79%) for investigating alternative delivery methods.
Conclusion: Australian medical cannabis users are risking legal ramifications, but consistent with
users elsewhere, claim moderate to substantial benefits from its use in the management of their
medical condition. In addition to strong public support, medical cannabis users show strong interest
in clinical cannabis research, including the investigation of alternative delivery methods.
Background
While cannabis has long been part of folk pharmacopeia,
there is a burgeoning body of research on its therapeutic
potential. This has largely drawn on scientific advances in
our understanding of the pharmacology of cannabis, and
its complex interactions with the central nervous system,
particularly endogenous brain reward pathways [1]. In
addition to basic experimental research, case reports, sur-
veys of people using cannabis for medical conditions and
prospective clinical trials of cannabis-based medicines are
consolidating the evidence that cannabis may play a role
in the management of some medical conditions. Authori-
tative reviews of this evidence indicate that cannabis has
therapeutic potential for conditions such as HIV- and can-
cer-related wasting, nausea and vomiting resulting from
Published: 04 October 2005
Harm Reduction Journal 2005, 2:18 doi:10.1186/1477-7517-2-18
Received: 17 August 2005
Accepted: 04 October 2005
This article is available from: http://www.harmreductionjournal.com/content/2/1/18
© 2005 Swift et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Harm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
Page 2 of 10
(page number not for citation purposes)
chemotherapy, neurological disorders such as multiple
sclerosis and chronic pain [1-4].
While current research reveals exciting therapeutic oppor-
tunities, there is an ongoing debate about the virtues of
obtaining such benefits from the complex chemical cock-
tail contained in the whole plant or from one or more
components isolated and developed into a synthetic phar-
maceutical product. This debate cross-cuts important
issues such as the difficulties of reliable dosing when
using the natural product, whether the potential harms of
smoking cannabis due to its ease of titration overshadow
its therapeutic benefits, and whether different medical
conditions will respond more favourably to the whole
plant or to different constituents in isolation or combina-
tion. However, underlying these issues is the reality that
most people who use cannabis medicinally do so by using
black market supplies of an illicit drug.
As with the opiates, evaluations of the therapeutic poten-
tial of cannabis occur in the context of a vigorous political
debate on the use of an illicit drug with dependence
potential for medicinal purposes. This situation is clearly
evident in the United States, where there is an ongoing
legal challenge by the Federal Government over the States'
rights to allow cannabis to be used by registered medical
users. Despite Canada's recent decision to provide a con-
trolled supply of natural cannabis to registered users, and
approvals for the marketing of Sativex, a pharmaceutical
cannabis extract, in some countries, currently most users
would rely on home-grown cannabis, or supplies
obtained from friends, families, dealers and medical com-
passion clubs.
To date, there has been little interest in Australia in for-
mally investigating the therapeutic potential of cannabis
or investigating the practices of current medical users. In
1999 the NSW State Government commissioned a Work-
ing Party to investigate the issue and recommend research
and legislative options. Among their recommendations
were: controlled clinical trials of cannabis, investigations
into delivery methods other than smoking, surveys of cur-
rent medical cannabis users and legislative amendments
to allow compassionate use [4]. Subsequently, in 2003
the NSW Government announced it would conduct clini-
cal trials, but despite generating significant publicity,
there has been no further commitment by the NSW Gov-
ernment on this issue. The 2004 National Drug Strategy
Household Survey found widespread public support for
medical cannabis use, with 68% supporting a change in
legislation to permit use for medical purposes and 74%
supporting a clinical trial of medicinal cannabis use [5]. It
is not known how many people use cannabis for medici-
nal purposes in Australia. Those who do use it engage in
an illegal behaviour and risk arrest. Those that rely on
black market supplies use a product of unknown source
and quality.
Several surveys in the US, UK, Germany and Canada [6-
12] have reported perceived improvements in a variety of
medical conditions following cannabis use. However, we
know very little about the experiences of Australian users,
and how they compare to findings in other studies. These
authors are aware of only two unpublished Australian
studies conducted in northern NSW; in 1998 a survey of
202 users recruited at the Nimbin HEMP Embassy [13],
and in 2003 a survey of 48 members of a medical canna-
bis information service [14].
This paper presents the results of a study of 128 users,
which aimed to learn more about their patterns of use,
experiences and concerns, and interest in participating in
a medical cannabis trial.
Methods
Sample
The sample comprised 128 people who used cannabis for
medical purposes. To be eligible for the study, participants
had to be living in Australia and to be currently using/
have previously used cannabis for medical purposes.
While the study targeted residents of Australia's most pop-
ulous state, NSW (pop: approximately 6.7 million), we
did not exclude participants from other parts of Australia
(total pop: approximately 20 million).
As it is not known how many Australians use cannabis for
medical purposes it was not possible to obtain a repre-
sentative sample of such users. As this was an exploratory
study to see who responded to a general call for participa-
tion in the survey, we did not target groups representing
people with specific medical conditions (e.g., HIV/AIDS,
multiple sclerosis) or hospital departments known to treat
patients who may benefit (e.g., oncology, chronic pain
clinics). Participants were primarily recruited from oppor-
tunistic media stories between November 2003 and
August 2004, in newspapers, on radio and television. In
addition, the Medical Cannabis Information Service
(MCIS) in Nimbin, NSW, offered to tell its members
about the survey and the International Association for
Cannabis as Medicine (IACM), in Germany, placed the
questionnaire on its website.
A total of 147 enquiries were received between December
2003 and August 2004 by telephone and email and
approximately 170 questionnaires distributed (some peo-
ple requested multiple copies to distribute). For example,
the media stories generated enquiries from several GPs
who said they would inform certain patients of the study.
Of the 131 questionnaires returned, 128 were used for
analysis (75% of questionnaires sent out). Of the threeHarm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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discarded questionnaires, one respondent was a recrea-
tional cannabis user and two had never used cannabis.
Questionnaire
The survey comprised an anonymous mail-out question-
naire, adapted from one developed by the MCIS in a
recent study of its members [14]. Several issues were cov-
ered, including medical conditions/symptoms experi-
enced, patterns of medical cannabis use, symptom relief
and effects of use, comparison of cannabis to other medi-
cations, source and legal concerns (e.g., arrest), other con-
cerns over use, opinion of family, friends and medical
personnel, and interest in participating in a cannabis trial.
The final version incorporated comments from research-
ers and clinicians interested in this issue.
Procedure
The study received ethics approval from the University of
New South Wales Social/Health Human Research Ethics
Advisory (HREA) Panel. Interested persons were screened
for eligibility over the phone and informed of the purpose
of the survey; assurances of anonymity and confidentiality
were provided. Questionnaires were mailed to partici-
pants, completed anonymously and returned in a
stamped, self-addressed envelope. Addresses were
destroyed when the questionnaire was posted.
Analyses
Data were entered into SPSS (Version 12.0.1). As this was
an exploratory study with a small sample size, this paper
reports descriptive statistics only. Percentages are pre-
sented for categorical data; means (for normally distrib-
uted) and medians (for skewed data) are presented for
continuous data. While data are usually presented on the
overall sample, gender and age differences are presented
for some variables, where they are of interest.
Results
Demographics
The sample was 63% male. Participants had a median age
of 45 yrs (range 24–88), with almost one third (31%)
aged 50 years or over, and one in ten (9%) aged 60 years
plus. While the study targeted NSW residents (who repre-
sented 58% of participants), responses came from across
Australia, especially Queensland (15%) and Victoria
(12%). Residents of other States and Territories each com-
prised less than 3% of participants.
Participants reported a wide range of medical conditions
and symptoms associated in the literature with the use of
medicinal cannabis (Table 1), most commonly chronic
pain (53%) and arthritis (38%). Approximately one in
five reported migraine (22%), weight loss (21%) and per-
sistent nausea (20%). However, depression was the most
commonly reported condition/symptom (60%). Up to 35
other conditions/symptoms were listed, most commonly
Table 1: Conditions/symptoms experienced, duration, and conditions/symptoms requiring cannabis relief (n = 128).
Condition (%) with condition Median duration (yrs) % used cannabis for relief of..*
Depression 60 10 56
Chronic pain 53 10 57
Arthritis 38 9 35
Migraine 22 18 17
Weight loss 21 4 26
Persistent nausea 20 6 27
Spinal cord injury 14 11 13
Spasms (spasticity) 13 8 16
Fibromyalgia 13 13 13
Wasting 13 5 11
ME (chronic fatigue) 13 16 13
Neuralgia/neuropathy 12 8 12
HIV/AIDS 9 15 8
Multiple sclerosis 7 9 7
Cancer 6 10 4
Other neurological disorder 6 5 6
PTSD 5 13 1 person
Irritable bowel syndrome 4 10 1 person
Glaucoma 3 29 2
*These figures do not necessarily equate with the % reporting a particular condition because some people reported using cannabis to relieve the 
particular symptoms (e.g., chronic pain, nausea) associated with a condition, rather than citing they used cannabis to relieve the condition itself (e.g., 
arthritis, cancer).Harm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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post traumatic stress disorder (PTSD) (5%) and irritable
bowel syndrome (4%). It is important to note that we did
not ask participants to distinguish between primary symp-
toms/conditions for which they sought treatment (e.g.,
cancer) and conditions which may have been secondary
to this (e.g., depression) or consequent to treatment (e.g.,
chronic nausea). Multiple conditions (mean = 3.7, SD =
2.1, range = 1–10), of lengthy duration, were the norm,
with three quarters (84%) reporting more than one con-
dition and two thirds (67%) at least three conditions.
Congruent with this picture, cannabis was used to relieve
multiple symptoms (median = 3, range = 1–12), espe-
cially chronic pain (57%), depression (56%), arthritis
(35%), persistent nausea (27%) and weight loss (26%).
Patterns of medical cannabis use
Participants had first tried cannabis for medical purposes
at a median age of 31 years (range = 14–77). More than
one quarter (29%) had discovered its therapeutic benefits
as a spin-off from recreational use; others had tried it fol-
lowing concerns about the side-effects of their medica-
tions (14%), or a belief their medications or treatment
were ineffective (13%), or had acted on the recommenda-
tion of a medical practitioner (10%) or friend (10%).
Table 2 presents data on patterns of medical use. Most
(85%) were currently using cannabis therapeutically, even
if sporadically. For those who had stopped, the main rea-
sons were: their inability to obtain a regular supply (9/19
people), its illegality (7/19), cost (7/19) and disliking the
side effects or route of use (each 3/19). Of those using
intermittently, many reported their use would be more
regular if it were more readily availability and cheaper.
Medical use was typically long-term and regular. Use of
less than one year was uncommon (12%), with more than
half (61%) having used it for at least six years; one in five
reported very long-term use (more than 20 years). Most
used at least weekly (75%), and more than half (59%)
used almost daily or daily. Approximately one in five
(22%) specified they used it "as required" for their condi-
tion (e.g., when pain was severe). Women tended to
report shorter term use than men (52% vs. 31% citing use
of 5 years or less).
It was most common for participants' medical use to be
stable (22%) or largely unchanged since they started
(17%), although it was most common for the amount
used to vary according to their condition (35%). About
one in ten indicated some increase in dose had been
required (12%), while few reported a decrease (5%).
Women tended to report more variable (44% vs. 29% of
men) or short term use (15% vs. 6% of men); men tended
to report an increase in the amount needed (17% vs. 4%
of women).
In addition to medical use, three quarters (80%) of partic-
ipants had used cannabis recreationally. Recreational use
was less common among older participants (75% and
97% of recreational users were aged less than 50 years and
65 years, respectively). For almost half (46%), use in the
past year had been solely medicinal, but the remainder
reported recent recreational use – 29% in the past week,
19% in the past month and a further 6% in the past year.
Route of use
While most people had tried multiple routes for relief,
overall smoking was the route most commonly reported
(91%). Approximately half the sample (49%) also








Current use 85 86 83
Length of use
<1 year 12 9 17
1–5 yrs 27 23 35
6–10 yrs 20 26 10
11–15 yrs 9 10 8
16–20 yrs 10 10 10
>20 yrs 21 23 19
Frequency of use (n = 126)
several times a day 39 45 29
6–7 days/wk 24 19 31
1–5 days/wk 14 14 13
less than weekly 2 3 2
very seldom 2 1 2
as required 20 18 23
Method(s) of use (n = 127)
eaten as cooked recipe 49 48 50
drunk as tea 7 8 6
smoked as cigarette (joint) 65 58 77
smoked as dry pipe (chillum) 24 28 19
smoked as water pipe (bong) 54 58 46
vaporiser 8 11 2
eaten as leaf/flower matter 3 4 2
Most helpful method of use (n = 126)
eaten as cooked recipe 16 15 17
drunk as tea 2 3 2
smoked as cigarette (joint) 31 26 40
smoked as dry pipe (chillum) 10 13 4
smoked as water pipe (bong) 33 36 29
vaporiser 2 3 2
other 6 5 6Harm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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smoked tobacco, and two thirds (64.1%) mixed their can-
nabis with tobacco.
Eating cannabis in cooked recipes was also very prevalent
(49%). While vaporisers are not readily available in Aus-
tralia, 8% had used them. In addition, four people had
used tinctures and one used it topically in the bath or as a
cream for a skin condition. Overall, smoking was also
considered to be the most helpful route of use for symp-
tom relief (74%), although concerns about this route of
use were widespread. Consistent with Australian research
on preferred route of use and age [15], older users (aged
50 years +) typically found joints the most helpful
method of use (41% vs. 26% of younger users), while
younger users preferred the use of waterpipes (43% vs.
13% of older users).
When asked to comment on the good and bad points of
different methods of ingestion the most consistent
response was that smoking of any form, particularly with
tobacco, was detrimental to respiratory function (and
health). This was of particular concern to non-smokers,
some of whom did not know how to cook cannabis reci-
pes. Despite attracting the bulk of negative comments, its
popularity seemed to lie with its instant effect, its ease of
titration and cost-effectiveness compared to the oral
route. It seemed to "do the job". Eating was seen to be a
much healthier option – it was "safer", tasty when cooked
in a recipe, less obvious than smoking and could be done
virtually anywhere. Some people liked its slow onset and
long-lasting effects, but others claimed difficulties with
titration and slow onset made it expensive and ineffective
for rapid symptom relief.
Effects of cannabis use
When asked to rate the overall effects of cannabis on a Lik-
ert scale ranging from "I feel a lot worse" to "gives me
great relief", cannabis was perceived to provide "great
relief" (86%) or a little relief (14%). No one believed it
had been detrimental to their condition or symptoms.
Positive ratings were ("great" or "good" relief) were also
typical for its ability to relieve specific symptoms (Table
3). In addition, several other symptoms were noted,
primarily insomnia (13% used for insomnia; of these
82% derived "great" relief).
Approximately three quarters of participants (71%)
claimed to have experienced a return of their symptoms or
condition on stopping cannabis, especially: pain (53% of
those who claimed a return of symptoms), depression or
anxiety (30%), insomnia (11%), spasm (10%) and nau-
sea/vomiting or lack of appetite (9%).
Only one in ten (11%) participants reported symptoms
they believed were unrelated to their medical condition
upon stopping cannabis, citing symptoms congruent with
cannabis withdrawal such as anxiety or mood disturbance
(including paranoia), insomnia, loss of appetite, restless-
ness and vivid dreams.
Comparison with other medicines
Almost two thirds (62%) of respondents claimed that
they decreased or discontinued their use of other medi-
cines when they started using cannabis medicinally. This
was more common in males (65% vs. 58% of females)
and older participants (aged 50 years +) (70% vs. 59%
among younger participants). For some people this was a
Table 3: Symptom relief (n = 128)






Nausea relief 48 56 44
Of these, received:
great relief 53 51 62
good relief 44 46 35
no effect 3 3 4
Pain relief 83 83 83
Of these, received:
great relief 55 49 65
good relief 45 52 35
no effect 0 0 0
Ability to cope emotionally 66 70 60
Of these, received:
great relief 45 40 54
good relief 54 58 46
no effect 1 2 0
Appetite stimulant 51 55 44
Of these, received:
great relief 52 55 48
good relief 46 46 48
no effect 2 0 5
Decrease in spasms/tremor 39 36 44
Of these, received:
great relief 43 43 43
good relief 55 54 57
no effect 2 4 0
Relief through relaxation 83 88 75
Of these, received:
great relief 72 69 78
good relief 28 31 22
no effect 0 0 0
* No-one reported their condition was made worseHarm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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substantial change, representing a shift away from
chronic, high-dose medication use.
Perhaps not surprisingly, cannabis was typically perceived
as superior to other medications in terms of undesirable
effects, and the extent of relief provided (Table 4). Thus,
cannabis was rated to produce equivalent (8%) or worse
side effects (3%) by a minority of therapeutic users. It was
considered to work "a bit" or "much better" than other
medicines, or to be the only source of relief, by more than
three quarters (82%). Two participants made the interest-
ing comment that cannabis worked differently  to other
medicines, so could not be directly compared.
Despite the very positive response to the use of cannabis,
nearly one half (41%; 36% of men and 50% of women)
found it did not help certain conditions/symptoms.
Almost one third (29%) said cannabis was less effective
for certain types of pain, or extreme pain, with a further
12% specifying migraine or headache pain. Nearly one in
ten (8%) reported no effect on depression or anxiety.
More than one in ten (14%) specified that while cannabis
could ease their symptoms and enabled them to cope,
they realised that it could not cure their underlying condi-
tion. Younger participants were more likely than older
participants to claim a condition not helped by cannabis
(45% vs. 32% of those aged 50 years +).
Supply issues
Participants obtained medical cannabis from multiple
sources (median = 1, range = 1–6; 44% had two or more
sources), especially friends or family (58%) and dealers
(42%). A substantial proportion grew their own (38%)
while few (6%) obtained it from a compassion club or
cooperative. Among those who purchased cannabis, the
median weekly outlay was $50 (range = $1–$500, n = 95).
When asked to comment on the variability of the canna-
bis they used, those who could obtain a consistent supply
of high quality cannabis that suited their needs were in the
minority. Typically, participants noticed variability along
a number of lines, such as potency, effectiveness, intoxica-
tion and side-effects, which made titration difficult. While
some noted the importance of factors such as the part of
the plant used (e.g., leaf versus head/buds), strain (e.g.,
sativa versus indica), soil and climate, the overwhelming
responses focussed on hydroponic versus soil-grown can-
nabis ("bush bud" or home grown cannabis), and home
grown cannabis versus purchased cannabis.
Hydroponic cannabis was almost universally unpopular
and was avoided where possible – despite its greater
potency, it was also considered shorter acting, produced
greater tolerance and worse side-effects than other canna-
bis. By comparison, soil-grown cannabis was perceived to
Table 4: Comparison of cannabis with other medications (n = 128 unless specified).
Total Male Female
Decreased or discontinued use of other medicines (n = 117*) 62% 65 58
Comparison of undesirable effects (n = 125)
Cannabis produced much worse effects than other medicines 1 0 2
Cannabis produced somewhat worse effects 2 4 0
Undesired effects about the same 8 8 9
Other meds produced somewhat worse effects than cannabis 16 14 19
Other medicines produced much worse effects than cannabis 41 40 43
I have no undesirable effects from cannabis 31 33 28
Other medicines work differently 1 1 0
Comparison of relief provided (n = 118*)
Other medicines work much better than cannabis 3 0 7
Other medicines work a bit better than cannabis 3 4 0
Other medicines work about the same as cannabis 9 8 9
Cannabis works a bit better than other medicines 13 11 15
Cannabis works much better than others medication 54 58 48
Only cannabis gives me relief from my condition 15 15 15
Other medicines work differently 2 0 4
Can't distinguish – use them together 1 1 2
Use cannabis to relieve side effects of other medicines 1 1 0
*Some people did not use other medications concurrentlyHarm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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be less unpleasantly potent, natural ("organic"), less
chemically treated, and with fewer side-effects. However,
it was also perceived as harder to get. Home grown canna-
bis was seen as the best method of obtaining a consistent,
safe supply of medicinal quality. A common response was
that purchased cannabis was not to be trusted, and that
unscrupulous growers who were more concerned with
yield and greed compromised the quality of their crop
with chemicals such as growth hormone and pesticides.
Concerns
A minority (13%) had no concerns over their medical can-
nabis use. Concerns over potential health effects (32%) or
the risk of dependence (21%) were overshadowed by
those relating to its illegal status (76%), the fear of being
arrested (60%) and cost (51%). Indeed, one quarter
(27%) claimed to have been arrested, cautioned or con-
victed in relation to their medical cannabis use, with this
outcome more commonly reported by men (31% vs. 19%
of women) and younger users (30% vs. 16% of users aged
50 years +). Other concerns mentioned (15%) were: the
stigma of using, issues around parenting, pregnancy and
relationships, availability, quality and difficulties in dose
adjustment.
Support from others and interest in clinical trial
Most participants had a regular doctor (90%) and about a
half had a regular specialist (55%). Virtually all (90%)
had informed a clinician of their therapeutic use, typically
reporting a supportive response from GPs (75% of those
told), specialists (74%) and nurses (81%). Family and
friends were largely considered supportive of the partici-
pant's use (71%).
Not surprisingly, there was widespread support for Gov-
ernment provision of cannabis to patients in a variety of
circumstances. At least three quarters supported the sup-
ply of cannabis to any patient who was permitted to use it
by being registered under a Government scheme (82%);
more specifically, those patients who: could not afford to
buy it on a regular basis (82%), could only purchase it on
the black market (81%), couldn't ensure a consistent sup-
ply (75%), or were worried about quality control issues
(77%). More than half endorsed the supply of patients
who did not know anyone capable of growing it (72%),
were concerned about hydroponically grown cannabis
(72%), or who needed a supply quickly (66%).
Although not all participants were NSW residents, there
was almost universal interest (89%) in participating in a
clinical trial, in which a controlled supply of cannabis was
grown and provided to registered medical cannabis users.
There was also strong, although lesser, interest in trying
alternative delivery methods such as a spray or tablet
(79%).
While for some people, the availability of any cannabis-
derived product that worked was their prime concern,
alternative delivery methods were considered attractive as
they obviated the necessity to smoke, removed concern
about engaging in illegal behaviour and having to access
the black market, and were more portable and acceptable
than smoking. The main caveats on an alternative were
that it was easy to titrate, quick, efficient, reliable and nat-
ural or safe – sprays and vaporisers were mentioned spe-
cifically by some as preferable to pills in this regard. A
clear theme was the desire to keep the holistic, natural
properties of cannabis rather than produce a chemical/
synthetic drug with numerous binding and carrying
agents. Nevertheless, there was recognition that different
medical conditions may require different approaches,
such as different active agents (e.g., THC versus other can-
nabinoids), strains or methods (e.g., slow release pill ver-
sus fast-acting spray).
The main reason for not supporting alternatives appeared
to be that using the whole plant in its natural state was
perceived to be the best method. In addition, for some the
ritual of cannabis use was perceived as part of its medici-
nal benefit. There was also concern at political interfer-
ence and its potential for exploitation and corruption in a
trial.
Discussion
This exploratory study examined the patterns of medicinal
cannabis use among a sample of 128 Australian adults
who responded to media stories about this issue. Firstly,
we need to acknowledge its limitations. As we do not
know how many Australians use cannabis medicinally or
their characteristics, we relied on the recruitment of vol-
unteers through purposive sampling. Instead of targeting
a particular group we used media stories disseminated
widely on the radio, television and in newspapers to
attract a cross-section of people. Thus, these results may
not be representative of the experiences of all medicinal
users, and may be affected by selection bias by excluding
those who did not have access to these media, who did
not wish to or could not contact us or did not return the
questionnaire. We also attracted participants whose expe-
riences with medical cannabis were typically positive, so
they have little to tell us about people who have not found
cannabis helpful or pleasant therapeutically. However,
they still provide important information on these people's
experiences, and raise important issues regarding the use
of black market supplies of the cannabis plant and the
development of cannabis-based pharmaceuticals. As the
questionnaire was self-completed, there was potential for
misunderstanding of the questions. However, the word-
ing was straightforward, contact details were provided in
the event of misunderstanding, and the results were
remarkably consistent across participants, which encour-Harm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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ages us that the questions were understood. Despite being
anonymous, several participants provided us with contact
details in case further information was needed, and wrote
additional comments about their experiences and atti-
tudes. In addition, many of the findings are remarkably
consistent with the findings of other local and interna-
tional studies, as indicated below.
People in this study reported regular, ongoing medical use
over quite long periods – with 61% using for more than
five years and 20% reporting very long-term use of more
than 20 years. However, as Ware and colleagues noted in
their study of almost 1000 medical users [10], this was a
group of chronically ill people with multiple long-stand-
ing conditions. The perceived need for alternative or addi-
tional symptom relief may reflect the fact that we recruited
a sample of particularly entrenched medicinal cannabis
users who were dissatisfied with conventional treatments,
that medicinal cannabis use is more likely to considered
an option by people who find conventional treatments
and medications unsatisfactory, or that many had been
exposed to its perceived medical benefits quite early due
to their recreational use. Larger studies addressing a broad
cross-section of users may better answer this question.
Consistent with the literature on the conditions for which
cannabis has been indicated, chronic pain, arthritis, per-
sistent nausea and weight loss were among the most com-
mon conditions for which cannabis relief was sought.
However, depression was the most common condition:
more than half (56%) used cannabis to relieve depres-
sion, and two thirds (66%) used it to cope emotionally,
universally obtaining great or good relief. Other studies
have also reported cannabis use for the relief of depres-
sion, although not at this level [8-10,14]. The relationship
between depression and cannabis use is controversial,
with recent literature indicating that cannabis use may be
implicated in depression and suicidal thoughts and
behaviours This would suggest that regular medicinal use
may be contraindicated by placing people at risk of depres-
sion or self-harm. However, we do not know the type or
aetiology of the depression cited by our participants.
Many may have experienced depression and stress associ-
ated with their physical condition, which may have been
alleviated along with any physical relief. The risk may also
be greatest among heavy, younger users and those who
may already be vulnerable to mental ill health due to their
life circumstances [16-18]. Medical cannabis use patterns
may not typically be regular enough to pose a great risk.
Regardless, it is important that people considering the use
of medical cannabis are aware of the risks of use [19]. A
recent paper [20] has suggested that THC and cannabid-
iol, two major components of cannabis, may help allevi-
ate bipolar disorder, recommending a pharmaceutical
product would be a safer option than crude cannabis, in
which the balance of components is variable.
Consistent with local and international research on peo-
ple with a variety of medical conditions [8-12,14], most
participants claimed moderate to substantial benefits
from cannabis, both in terms of their overall condition
and management of individual symptoms. It was typically
considered more effective and less aversive than other
medications in managing their condition(s), the symp-
toms of which commonly re-emerged upon stopping
(71%). While their use was often complementary to other
medications and treatment, 62% had decreased or discon-
tinued use of other medications when they commenced
medicinal cannabis use. Nevertheless, cannabis was not a
panacea – it did not help all conditions, particularly cer-
tain types of pain, and there was recognition that while it
substantially improved quality of life it was not a cure.
This is not necessarily surprising, as overall well-being and
specific symptoms have multiple causes and can be
affected by several factors, and is borne out by recent con-
trolled clinical trials, for example, on chronic pain [21].
As others have reported (e.g., [8-10] we also found that in
addition to medical use, recreational use was common:
most (80%) had used cannabis recreationally, with about
one half (54%) of these reporting some recent use.
Indeed, 29% had discovered its therapeutic potential
through their recreational use. One participant raised the
issue that part of the therapeutic effect for them was the
ritual of use and the "high" experienced [6]. This
demonstrates the difficulty of precisely identifying the
therapeutic component when people are using the natural
plant matter, and will continue to present a challenge for
the development of cannabis pharmaceuticals. While
some people may find the illegality, route of use and psy-
choactive effects of natural cannabis undesirable and pre-
fer a manufactured pharmaceutical product, several in this
survey claimed to prefer the holistic delivery of all the
compounds present when using the natural plant. We
need to know more about the effect of the different active
chemicals on medical conditions and how their therapeu-
tic potential is mediated by the context of use.
Nonetheless, this was not simply a sample of recreational
users, especially as we attracted many older users who
used exclusively for medical reasons (75% of those aged
50 years+). They did not fit the recreational user stereo-
type, were willing to take the risk of using an illicit drug,
exposure to the illicit drug market and the possibility of
arrest to gain symptom relief. Indeed, the most common
concern over medicinal use was its illegality, fear of arrest
and cost (all >50%). One quarter (27%) of participants
had experienced legal ramifications due to their use. Sev-
eral people commented that they had no alternative thanHarm Reduction Journal 2005, 2:18 http://www.harmreductionjournal.com/content/2/1/18
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using an illegal drug, claiming that other medicines with
negative and toxic effects (e.g., opiates) were legally pre-
scribed, and that if nothing else worked for them they had
the right to access cannabis without fear or stigma. Several
made pleas for medical cannabis use to be treated as a
medical, rather than a legal, issue, as their health and
quality of life were at stake.
Smoking was the most common method of use; in addi-
tion, many were tobacco smokers or mixed cannabis with
tobacco. Given the similarities between cannabis and
tobacco smoke this is of particular concern for people
who are ill, especially those with compromised immune
systems. Despite acknowledgement of the risks of smok-
ing and concerns expressed over its effects, it was consid-
ered the most helpful route of use. While eating was
perceived as much healthier, until satisfactory solutions
are achieved on titration and dosing issues, smoking will
no doubt continue to be a popular method of obtaining
relief.
Cannabis dependence was a concern for one in five partic-
ipants (21%). This study provided indirect evidence that
participants were unlikely to experience withdrawal
symptoms on ceasing medical use, but this was only a
crude measure. While the risk of dependence is probably
low when used medicinally, this risk needs to be weighed
up with the other concerns of the patient – for example, it
may be low on the list of concerns for those with terminal
illness [19].
Finally, participants reported that family and friends were
likely to know about and support their medical cannabis
use. These data also indicate that the medical profession is
encountering, and frequently supporting, patients who
use cannabis for symptom relief. Given their central role
in the management of illness, it is important that clini-
cians are educated about the effects of cannabis, in order
to assist patients in making informed decisions about
their treatment. There was also clearly great interest
among participants in a clinical trial and scope to investi-
gate methods of delivery that avoid the health concerns
associated with smoking cannabis, keeping in mind that
some participants were reluctant to use a pharmaceutical
product. In addition to distrust of unscrupulous partici-
pants in the black market, some were also distrustful of
Government's motives and role in therapeutic research. It
is therefore vital that any clinical trials are conducted in a
rigorous, independent manner.
Conclusion
Overall, these findings are consistent with those of other
surveys, in revealing the perceived effectiveness of canna-
bis for the relief of symptoms associated with several med-
ical conditions. While a small study, it has several
implications. Firstly, people are risking the use of an illicit
drug for its perceived therapeutic effects, and in some
cases being arrested. Secondly, they are informing their
clinicians about their medical use and frequently receiv-
ing support, highlighting the importance of ensuring cli-
nicians are informed about cannabis. Finally, in addition
to strong public support, medical cannabis users show
strong interest in clinical cannabis research, including the
investigation of alternative delivery methods.
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